Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA publishes guidance on CLIA waivers

This article was originally published in Clinica

Executive Summary

The US FDA has published revised guidance for device manufacturers seeking to get their products waived from regulatory oversight under the Clinical Laboratory and Improvement Amendments of 1988 (CLIA) law. In the regulations published to implement the CLIA in 1992, waived tests were defined as simple laboratory examinations and procedures that were cleared by the FDA for home use, or that employ methodologies that -are simple and accurate as to render the likelihood of erroneous result negligible", or that pose no reasonable risk of harm to the patient if the test is performed incorrectly.

You may also be interested in...



Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Krka Responds To Romanian Allegations

Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.

Topics

UsernamePublicRestriction

Register

MT046170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel